In 2022, Siddique et al. reported that galantamine effectively inhibits Aβ42 aggregation mainly by reducing AChE activity and promoting GSH-Px levels in the brain at 57 days in the transgenic Drosophila model of AD [109]. This evidence concerns the gene ACHE and Alzheimer disease.